Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factors for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med. 2002;162:1021–7.
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella Pneumoniae. Infect Control Hosp Epidemiol. 2004;25:860–7.
Bradford PA. Extended spectrum-β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–51.
Peterson DL, Ko WC, Gottberg AV, Mohapatra S. Antibiotic therapy for Klebsiella pneumonia bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis. 2003;39:31–7.
Stone PW, Gupta A, Loughrey M, Della-Latta P, Cimiotti J, Larson E, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2003;25:601–6.
Kim HS, Kim JI, Chan C. Monitoring of antimicrobial resistance on non-tertiary hospitals in Korea, 2007–2013. Public Health Wkly Rep. 2015;8:1092–5.
Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010;23:160–201.
Piroth L, Aube H, Doise JM, Vincent-Martin M. Spread of extended-spectrum β-lactamase-producing Klebsiella pneumonia: are β-lactamase inhibitors of therapeutic value? Clin Infect Dis. 1998;27:76–80.
Harris PNA, Yin M, Jureen R, Chew J, Ali J, Paynter S, et al. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2015;4:14.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteremia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–803.
Tamma PD, Rodriguez-Bano J. The use of non-carbapenem, β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin Infect Dis. 2017;64:972–80.
Pletz MW, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004;48:3765–72.
Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski U, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413–31.
Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, LaBombardi VJ, DiPersio J. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007–2008: results of the study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother. 2010;54:3031–4.
Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (study for monitoring antimicrobial resistance trends). Int J Antimicrob Agents. 2010;36:408–14.
Belaaouaj A, Lapoumeroulie C, Canica MM, Vedel G, Nevot P, Krishnamoorthy R, et al. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol Lett. 1994;120:75–80.
Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents. 2005;26:463–72.
Xu J, Duan X, Wu H, Qi Z. Surveillance and correlation of antimicrobial usage and resistance of pseudomonas aeruginosa: a hospital population-based study. PLoS One. 2013;8:e78604.
Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient sample. Epidemiol Health. 2014;36:e2014008.
World Health Organization. 2016. WHO Collaborating Centre for Drug Statistics Methodology. Structure and principles. http://www.whocc.no/atc/structure_and_principles. Accessed 2 Aug 2017.
Goossens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–87.
Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15:12-5.
Antimicrobial Resistance Newsletter. Research Institute of Bacterial Resistance and Department of Laboratory Medicine, Severance Hospital, Seoul. Republic of Korea.
Research Institution of Bacterial Resistance. http://www.whonetkorea.org. Accessed 2 Aug 2017.
Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement M100-S19. Wane: Clinical and Laboratory Standard Institute; 2009.
Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility disk susceptibility test; Approved standard. 11th ed. Wane: Clinical and Laboratory Standards Institute; 2012.
Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Wane: Clinical and Laboratory Standard Institute; 2013.
Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH. Network for antimicrobial resistance surveillance. Surveillance and correlation of antibiotic prescription and resistance of gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010;5:1173–8.
Gilca R, Fortin E, Frenettte C, Longtin Y, Gourdeau M. Seasonal variation in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada. J Antimicrob Chemother. 2012;56:639–46.
Cowperwait PSP, Metcalfe AV. Introductory time series with R. New York: Springer; 2009.
Box GEP, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control, 3rd ed. Englewood cliffs, NJ: prentice hall, 1994. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res. 1996;5:3–22.
Hyndman RJ, Athanasopoulos G. Forecasting; principles and practice. New York: O Texts; 2014.
Ng TM, Khong WX, Harris PNA, De PP, Chow A, Tambyah PA, et al. Empiric piperacillin-Tazobactam versus Carbapenems in the treatment of Bacteraemia due to extended- Spectrum Beta-lactamase-producing Enterobacteriaceae. PLoS One. 2016;11:e0153696.
Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis. 2012;7:1–8.
Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YC, et al. Correlation between antibiotic consumption and resistance of gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J Antimicrob Chemother. 2011;66:1374–82.
Jacoby TS, Kuchenbeckers RS, Dos Santos RP, Magedanz L, Guzatto P, Moreira LB. Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. J Hosp Infect. 2010;75:23–7.
Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004;48:1295–9.
Liu X, Thungrat K, Boothe DM. Occurrence of OXA-48 carbapenemase and other β-lactamase genes in ESBL-producing multidrug resistant Escherichia coli from dogs and cats in the United States, 2009-2013. Front Microbiol. 2016;7:e1057.
Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999. Emerg Infect Dis. 2002;8:473–8.
Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother. 2004;48:1934–40.
Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect. 2005;11:4–16.
Yoon YK, Park GC, An H, Chun BC, Sohn JW, Kim MJ. Trends of antibiotic consumption in Korea according to national reimbursement data (2008–2012): a population-based epidemiologic study. Medicine. 2015;94:e2100.
Livorsi D, Comer A, Matthias MS, Perencevich EN, Bair MJ. Factors influencing antibiotic-prescribing decisions among inpatient physicians: a qualitative investigation. Infect Control Hosp Epidemiol. 2015;36:1065–72.
Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, et al. Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol. 2008;29:615–22.